Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
the U.S. Food and Drug Administration (FDA) approved a supplemental new
drug application (sNDA) for the use of KALYDECO ® (ivacaftor)
in people with cystic fibrosis (CF) ages 6 and older who have the R117H
mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene.
for U.S. Food and Drug Administration Approves KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation investment picks